(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 8.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.56%.
Veracyte's revenue in 2025 is $463,393,000.On average, 4 Wall Street analysts forecast VCYT's revenue for 2025 to be $38,665,489,743, with the lowest VCYT revenue forecast at $38,468,136,923, and the highest VCYT revenue forecast at $38,985,013,356. On average, 4 Wall Street analysts forecast VCYT's revenue for 2026 to be $42,282,606,681, with the lowest VCYT revenue forecast at $41,497,346,077, and the highest VCYT revenue forecast at $43,377,679,887.
In 2027, VCYT is forecast to generate $46,361,936,454 in revenue, with the lowest revenue forecast at $44,328,419,264 and the highest revenue forecast at $48,219,089,139.